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Abstract
Individual and ward risk factors for P. aeruginosa-induced urinary
tract infection in the case of nosocomial urinary tract infection
in the intensive care unit were determined with hierarchical
(multilevel) logistic regression. The 2004–2006 prospective
French national intensive care unit nosocomial infection surveil-
lance dataset was used and 3252 patients with urinary tract
infection were included; 16% were infected by P. aeruginosa. Indi-
vidual risk factors were male sex, duration of stay, antibiotics at
admission and transfer from another intensive care unit. Ward
risk factors were patient turnover and incidence of P. aeruginosa-
infected patients.
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Rates of urinary tract infection (UTI) remain high in intensive
care units (ICUs) despite major advance in infection control
measures and antimicrobial therapy [1–3]. Pseudomonas aeru-
ginosa UTIs are associated with high mortality and morbidity
and require the use of a limited number of antibiotics [1,4].
A delay in administration of effective therapy may cause
severe adverse outcomes and overuse of anti-Pseudomonal
agents may lead to increased resistance rates and limit future
treatment options [5,6]. Therefore, in the case of a nosoco-
mial UTI, it would be useful for empirical therapy to distin-
guish between patients with and without P. aeruginosa. This
study investigated patient and ICU (ward) risk factors for
P. aeruginosa-induced UTI in nosocomial UTI.
The national French nosocomial infection surveillance in
the ICU (REA-RAISIN: REAnimation Re´seau d’Alerte Investi-
gation et Surveillance des Infections Nosocomiales) 2004–
2006 dataset was used [7]. Participating ICUs prospectively
collected four nosocomial infections (pneumonia, UTI, cathe-
ter-related infection and bacteraemia) with micro-organism
and drug resistance patterns. Patients admitted for more than
48 h were included and followed-up until discharge. On
admission, the following patient characteristics were col-
lected: age, gender, diagnosis (medical, surgical), immunodeﬁ-
ciency status, Simpliﬁed Acute Physiology Score (SAPS II
score), antibiotic treatment and trauma. Information on
where the patient came from was also collected (origin from
another ICU, medical or surgical unit or from home). Invasive
devices (mechanical ventilation, urinary catheter, central vas-
cular catheter) were recorded daily during the ICU stay. The
number of beds and the type of ICU (medical, surgical and
polyvalent, i.e. medical and surgical) were collected for each
ICU. Monthly patient turnover in the ICU was calculated
from the ratio of the number of patients admitted per month
to the number of beds in the ICU; the mean incidence of
P. aeruginosa-infected patients was calculated from the ratio
of the number of patients with a P. aeruginosa infection (not
only UTI) to the total number of patients (percentage).
Nosocomial urinary tract infection was deﬁned as a UTI
occurring 48 h after ICU admission. Patients had at least one
of the following signs or symptoms with no other recognized
cause: fever (>38C), urgency, frequency or suprapubic ten-
derness and a positive urine culture (with urinary catheter,
‡105 microorganisms/mL of urine with no more than two
species of microorganisms; without urinary catheter, ‡103
microorganisms/mL with no more than two species of
microorganisms and ‡104 WBC/mL) [3,8].
Only the ﬁrst UTI was studied. Patients with P. aeruginosa
UTI were compared with patients with non-P. aeruginosa
UTI. Hierarchical (two levels, patient and ICU) logistic
regression was performed with MLwiN version 2.15, centre
for multilevel modelling University of Bristol. We ﬁrst esti-
mated an ‘empty’ model (model A), which only included a
random intercept and allowed us to detect the existence of
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a possible contextual dimension for P. aeruginosa UTI. There-
after, we included the individual characteristics in the model
(model B) to investigate the extent to which ICU level differ-
ences were explained by the individual composition of the
ICU. Finally, we added the ICU variables (model C) to inves-
tigate whether P. aeruginosa UTI was conditioned by speciﬁc
ICU characteristics [9].
A total of 195 different ICUs were included: 75% polyva-
lent ICU, 13% medical ICU and 12% surgical ICU. Geograph-
ical distribution was representative of national ICU
distribution. Median duration of stay for these ICUs (all
patients included) was 11 days (5–57 days), median propor-
tion of patients with a urinary catheter was 80% (13–98),
median patient turnover was four patients per bed per
month (0.6–11), and median incidence of P. aeruginosa-
infected patients was 3% (0–14%).
We found 3252 patients with UTI and 525 (16%) with
P. aeruginosa UTI. Nine per cent of P. aeruginosa UTI were
followed by P. aeruginosa pneumonia (median delay of occur-
rence after the UTI, 9 days) and 3% by P. aeruginosa bactera-
emia (median delay of occurrence after the UTI, 4 days).
Patients’ characteristics and results of univariate analysis are
reported in Table 1. Results of multivariate analysis are pre-
sented in Table 2. Probability of P. aeruginosa UTI was associ-
ated with male sex, transfer from another ICU, duration of
ICU stay before UTI, antibiotics at admission, ICU incidence
of P. aeruginosa-infected patients and ICU patient turnover.
The residual heterogeneity between ICUs (MOR = 1.47) was
of greater relevance than the impact of the length of stay
before UTI (OR = 1.02) and of the same relevance as anti-
biotics at admission (OR = 1.47).
Multilevel modelling allowed analyzing data in a simple and
appropriate way [9]. Selection and measure biases were lim-
ited, as several ICUs participated with the same methodology.
There are few data available concerning predictive factors
of P. aeruginosa in the case of nosocomial UTI in the ICU but
TABLE 1. Main characteristics of the
3252 patients according to their type








UTI (n = 2727) p
Sex-ratio (M/F) 2.0 0.9 <10)2
Mean (SD)* Mean (SD)*
Age (year) 64.5 (17.3) 63.8 (16.6) ns
SAPS II score 57.6 (93.8) 53.9 (85.1) ns
Duration of stay in the ICU before UTI (day) 23.5 (12.9) 15.2 (14.7) <10)2
Duration of urinary catheterization before UTI (day) 22.2 (18.4) 14.2 (14.1) <10)2
n (%) n (%)
Origin at admission
Patient with no hospitalization before admission 262 (50%) 1473 (55%) _
Patient from medical or surgical unit 214 (41%) 1088 (40%) ns
Patient from an ICU 45 (9%) 139 (5%) <0.05
Antibiotics at admission 351 (67%) 1444 (54%) <0.05
Trauma patient 62 (12%) 370 (13%) ns
Type of diagnosis
Medical 358 (68%) 1940 (71%) ns
Surgical 166 (32%) 774 (29%)
Immunodeﬁciency 458 (12%) 2383 (11%) ns
Urinary catheterization before UTI 517 (98%) 2676 (98%) ns
Mortality 131 (25%) 654 (24%) ns
*SD, standard deviation; ns, non-signiﬁcant.
TABLE 2. Risk factors for P. aerugin-
osa in the case of nosocomial urinary
tract infection (UTI); multivariate
analysis
Model A Model B Model C
Intercept )1.625 (0.060) )2.359 (0.121) )2.364 (0.124)
Individual (patient) level variables OR (95% CI) OR (95% CI)
Male sex 1.97 (1.61–2.42) 2.00 (1.62–2.47)
Origin at admission
Patient from home – –
Patient from medical or surgical unit 1.03 (0.84–1.37) 1.07 (0.86–1.33)
Patient from an ICU 1.91 (1.29–2.81) 1.85 (1.24–2.77)
Antibiotics at admission 1.47 (1.19–1.83) 1.39 (1.11–1.73)
Duration of stay in the ICU before UTI 1.02 (1.02–1.03) 1.02 (1.01–1.03)
Ward (ICU) level variables
Patient turnover 1.08 (1.02–1.15)
Incidence of P. aeruginosa-infected patients 1.09 (1.04–1.15)
MOR (95% CrI) 1.48 (1.38–1.60) 1.47 (1.37–1.56) 1.40 (1.30–1.51)
ICC 0.048 0.047 0.037
OR, odds ratio; 95% CI, 95% conﬁdence interval; SE, standard error; MOR, median odds ratio; CrI, credible
interval; ICC, intraclass correlation.
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some patient factors were previously identiﬁed [10–14]. This
study sought to create patient and ICU proﬁles associated
with the risk of P. aeruginosa UTI. According to our results,
ICU physicians facing a nosocomial UTI should suspect
P. aeruginosa in the case of a male patient, transferred from
another ICU with antibiotics at admission and long duration
of stay, especially in an ICU with high patient turnover and
high rates of P. aeruginosa-infected patients.
Neurogenic bladder, history of prostatic surgery, urinary
tract procedures, a foreign body in the urinary tract, chronic
corticosteroids and antibiotics during the stay were also found
to be associated with the risk of P. aeruginosa UTI [10,13].
Neither antibiotic use during ICU stay nor type of antibiotics
at admission was collected in REA-RAISIN. Many studies
showed selection of P. aeruginosa by antibiotic use [10,11,13].
Imipenem, ciproﬂoxacin, levoﬂoxacin, piperacillin, tazocillin,
broad-spectrum cephalosporins, aminoglycosides and antibiot-
ics inactive against P. aeruginosa were associated with high inci-
dence rates of P. aeruginosa [11,15–17]. Antibiotic therapy
could lead to an alteration in the resident microﬂora, facilitat-
ing colonization with P. aeruginosa prior to UTI [10].
This study determined ICU characteristics associated with
P. aeruginosa UTI, even if individual characteristics remain
predominant. Incidence of P. aeruginosa-infected patients is
likely to be a marker of both ICU ecology (colonization
pressure) and cross-transmission rates that are unique to
each ICU. A high patient turnover can reduce the time avail-
able to perform environmental cleaning between two
patients or can be a marker of elevated nurse stafﬁng
[18,19]. Previously, the number of P. aeruginosa carriers,
nurse to patient ratio and compliance with infection control
measures were related to P. aeruginosa acquisition [15,20].
To conclude, routine national nosocomial infection surveil-
lances can help in detecting new risk factors for infections
with speciﬁc microorganisms. We identiﬁed ward risk factors
for Pseudomonas aeruginosa in the case of UTI in the ICU.
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